Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.
Nelson, AS; Heyenbruch, D; Rubinstein, JD; Sabulski, A; Jodele, S; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; et al.
Blood Advances.
2020;
4:5745-5754.
Non-Tuberculous Mycobacterial Infection in Hematopoietic Cell Transplant.
Sabulski, A; Davies, SM; Paulsen, G; Kumar, A; Grimley, M; Chandra, S.
Journal of Clinical Immunology.
2020;
40:1171-1175.
CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study.
Khandelwal, P; Fukuda, T; Teusink-Cross, A; Kashuba, AD M; Lane, A; Mehta, PA; Marsh, RA; Jordan, MB; Grimley, MS; Myers, KC; et al.
Bone Marrow Transplantation.
2020;
55:1552-1559.
Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy.
Rubinstein, JD; Zhu, X; Lutzko, C; Leemhuis, T; Cancelas, JA; Jodele, S; Bollard, CM; Hanley, PJ; Davies, SM; Grimley, MS; et al.
Blood Advances.
2020;
4:3252-3257.
Graft Versus Host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta Thalassemia Major with Busulfan, Fludarabine, and Thiotepa.
Khandelwal, P; Yeh, RF; Yu, L; Lane, A; Dandoy, CE; El- Bietar, J; Davies, SM; Grimley, MS.
Transplantation.
2020;
Publish Ahead of Print.
Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
Teusink-Cross, A; Davies, SM; Grimley, MS; Chandra, S; Flannery, A; Dandoy, CE; Nelson, AS; Marsh, RA; Jacoby, B; Lane, A; et al.
Pediatric Transplantation.
2020;
24.
EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects.
Rubinstein, JD; Burns, K; Absalon, M; Lutzko, C; Leemhuis, T; Chandra, S; Hanley, PJ; Keller, MD; Davies, SM; Nelson, A; et al.
Pediatric Blood and Cancer.
2020;
67.
High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.
Lee, LH; Krupski, C; Clark, J; Wunderlich, M; Lorsbach, RB; Grimley, MS; Burwinkel, M; Nelson, A; Kumar, AR.
Blood Advances.
2020;
4:717-727.
Patient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-gamma Responsive Pathway.
Haake, K; Neehus, A; Buchegger, T; Kuehnel, MP; Blank, P; Philipp, F; Oleaga-Quintas, C; Schulz, A; Grimley, M; Goethe, R; et al.
Cells.
2020;
9:483-483.
CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells.
Khandelwal, P; Chaturvedi, V; Owsley, E; Lane, A; Heyenbruch, D; Lutzko, CM; Leemhuis, T; Grimley, MS; Nelson, AS; Davies, SM; et al.
Biology of Blood and Marrow Transplantation.
2020;
26:1-6.